Mortality and causes of death in families with the factor V leiden mutation (resistance to activated protein C)

Blood

Volumn 89, Issue 6, 1997, Pages 1963-1967

  Hille, Elysée T M ^a   Westendorp, Rudi G J ^a   Vandenbroucke, Jan P ^a   Rosendaal, Frits R ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5;

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; CAUSE OF DEATH; FEMALE; GENE MUTATION; HETEROZYGOTE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; THROMBOEMBOLISM;

EID: 0030968522     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.6.1963     Document Type: Article

References (31)

1. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 90:1004, 1993
2. Koster T, Rosendaal FR, Ronde de H, Briët E, Vandenbroucke JP, Bertina RM: Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342:1503, 1993
3. Svensson PJ, Dahlbäck B: Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330:517, 1994
4. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, Ronde de H, Velden van der PA, Reitsma PH: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369:64, 1994
5. Rosendaal FR, Bertina RM, Reitsma PH: Evaluation of activated protein C resistance in stored plasma. Lancet 343:1289, 1994
6. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR: The risk of venous thrombosis among users of oral contraceptives is increased in carriers of the factor V Leiden mutation (hereditary APC-resistance). Lancet 344:1453, 1994
7. Lindblad B, Svensson PJ, Dahlbäck B: Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C. Lancet 343:917, 1994
8. Rosendaal FR, Heijboer H, Briët E, Büller HR, Brandjes DPM, Bruin de K, Hommes DW, Vandenbroucke JP: Mortality in hereditary antithrombin-III deficiency - 1830 to 1989. Lancet 337:260, 1991
9. Allaart CF, Rosendaal FR, Noteboom WMP, Vandenbroucke JP, Briët E: Survival in families with hereditary protein C deficiency, 1820 to 1993. Br Med J 311:910, 1995
10. World Health Organization: Manual of the International Statistical Classification of Disease, Injuries, and Causes of Death (Fifth Revision). Geneva, Switzerland, World Health Organization, 1940
11. World Health Organization: Manual of the International Statistical Classification of Disease, Injuries, and Causes of Death (Sixth Revision). Geneva, Switzerland, World Health Organization, 1948
12. World Health Organization: Manual of the International Statistical Classification of Disease, Injuries, and Causes of Death (Seventh Revision). Geneva, Switzerland, World Health Organization, 1957
13. World Health Organization: Manual of the International Statistical Classification of Disease, Injuries, and Causes of Death (Eighth Revision). Geneva, Switzerland, World Health Organization, 1968
14. World Health Organization: Manual of the International Statistical Classification of Disease, Injuries, and Causes of Death (Ninth Revision). Geneva, Switzerland, World Health Organization, 1977
15. Mackenbach JP: Secundaire doodsoorzaken (in Dutch). T Soc Gezondheidsz 65:524, 1987
16. Mackenbach JP, Kunst AE, Lautenbach H, Bijlsma F, Oei YB: Competing causes of death and analysis using multiple-cause-of-death data from the Netherlands. Am J Epidemiol 141:466, 1995
17. Coleman M, Douglas A, Hermon C, Peto J: Cohort study analysis with a FORTRAN computer program. Int J Epidemiol 15:134, 1986
18. Breslow NE, Day NE: Rates and rate standardization, in Breslow NE, Day NE, Heseltine E (eds): Statistical Methods in Cancer Research. Volume II - The Design and Analysis of Cohort Studies. Oxford, UK, Oxford University, 1987, p 48
19. Holm J, Zöller B, Svensson PJ, Berntop E, Erhardt L, Dahlbäck B: Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 344:952, 1994
20. Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Mäkelin R, Hämäläinen L, Palomäki H, Kaste M: Arg506Gln factor V mutation (factor V Leiden) in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. Thromb Haemost 73:558, 1995
21. März W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I: Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 345:526, 1995
22. Samani NJ, Lodwick D, Martin D, Kimber P: Resistance to activated protein C and risk of premature myocardial infarction. Lancet 344:1709, 1994
23. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Cambien F: Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance. Lancet 345:321, 1995
24. Bockxmeer van FM, Baker RI, Taylor RR: Premature ischaemic heart disease and the gene for coagultion factor V. Nature Med 1:385, 1995
25. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Eisenberg PR, Miletich: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912, 1995
26. Launbjerg J, Egeblad H, Heaf J, Nielsen NH, Fugleholm AM, Ladefoged K: Bleeding complications to oral anticoagulant therapy: Multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med 229:351, 1991
27. Meer van der FJM, Rosendaal FR, Vandenbroucke JP, Briët E: Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153:1557, 1993
28. Vandenbroucke JP, Meer van der FJM, Helmerhorst FM, Rosendaal FR: Factor V Leiden: Should we screen oral contraceptive users and pregnant women? Br Med J 313:1127, 1996
29. Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet 346:1133, 1995
30. Mari D, Mannucci PM, Duca F, Bertolini S, Franceschi C: Mutant factor V (Arg506Gln) in healthy centenarians. Lancet 347:1044, 1996
31. Rosendaal FR, Roster T, Vandenbroucke JP, Reitsma PH: High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 85:1504, 1995